Human Pharmaceutical Portfolio

Tysabri 300 mg Injection

Product information from the Times Medicament supplied portfolio. Contact our export team to confirm current sourcing options, market requirements and commercial availability.

Molecule / StrengthNatalizumab 300 mg
ManufacturerBiogen Idec Biotech India Pvt Ltd
CategoryMultiple Sclerosis
This product is listed in the supplied Times Medicament unregistered product portfolio. Listing does not by itself confirm registration, licensing or availability in any specific country. Market-specific confirmation is required.